PGD2 effects on rodent behavior and EEG patterns in cats

Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes

To meet the new challenges of modern lifestyles, we often compromise a good night's sleep. In preclinical models as well as in humans, a chronic lack of sleep is reported to be among the leading causes of various physiologic, psychologic, and neurocognitive deficits. Thus far, various endogenous mediators have been implicated in inter-regulatory networks that collectively influence the sleep-wake cycle. One such mediator is the lipocalin-type prostaglandin D2 synthase (L-PGDS)-Prostaglandin D2 (PGD2)-DP1 receptor (L-PGDS-PGD2-DP1R) axis. Findings in preclinical models confirm that DP1R are predominantly expressed in the sleep-regulating centers. This finding led to the discovery that the L-PGDS-PGD2-DP1R axis is involved in sleep regulation. Furthermore, we showed that the L-PGDS-PGD2-DP1R axis is beneficial in protecting the brain from ischemic stroke. Protein sequence homology was also performed, and it was found that L-PGDS and DP1R share a high degree of homology between humans and rodents. Based on the preclinical and clinical data thus far pertaining to the role of the L-PGDS-PGD2-DP1R axis in sleep regulation and neurologic conditions, there is optimism that this axis may have a high translational potential in human therapeutics. Therefore, here the focus is to review the regulation of the homeostatic component of the sleep process with a special focus on the L-PGDS-PGD2-DP1R axis and the consequences of sleep deprivation on health outcomes. Furthermore, we discuss whether the pharmacological regulation of this axis could represent a tool to prevent sleep disturbances and potentially improve outcomes, especially in patients with acute brain injuries.

Prostaglandin d2 induced potentiation of the anticonvulsant actions of phenobarbitone and phenytoin in rats. Role of serotonin

Prostaglandin D2 (PGD2) produced a dose-related potentiation of the anticonvulsant actions of sub-effective doses of phenobarbitone and phenytoin against maximal electroshock-induced seizures in rats. PDG2-induced potentiation of phenobarbitone and phenytoin was significantly attenuated following pretreatment with centrally administered 5,6-dihydroxytryptamine, a selective neurotoxin for serotonergic neurones, p-chlorophenylalanine, a specific inhibitor of serotonin biosynthesis, and methysergide, a serotonin receptor antagonist, indicating that the potentiation was serotonin-mediated.

Prostaglandins and central serotonergic activity in the rat

Pharmacological and biochemical studies indicate that prostaglandins (PGs) exert a modulatory influence on rat brain serotonergic activity. With several experimental approaches, it has been shown that PGEs and PGD2 facilitate central serotonergic activity in rats. On the contrary, PGF2α not only inhibits rat brain serotonergic activity but also antagonizes the facilitatory effect of the other PGs. The studies support the proposed neuromodulatory role for PGs in central synaptic transmission.

Prostaglandin D2 and sleep regulation

Prostaglandin (PG) D2 is recognized as the most potent endogenous sleep-promoting substance whose action mechanism is the best characterized among the various sleep-substances thus far reported. The PGD2 concentration in rat cerebrospinal fluid (CSF) shows a circadian change coupled to the sleep-wake cycle and elevates with an increase in sleep propensity during sleep deprivation. Lipocalin-type PGD synthase is dominantly produced in the arachnoid membrane and choroid plexus of the brain, and is secreted into the CSF to become beta-trace, a major protein component of the CSF. The PGD synthase as well as the PGD2 thus produced circulates in the ventricular system, subarachnoidal space, and extracellular space in the brain system. PGD2 then interacts with DP receptors in the chemosensory region of the ventro-medial surface of the rostral basal forebrain to initiate the signal to promote sleep probably via the activation of adenosine A2A receptive neurons. The activation of DP receptors in the PGD2-sensitive chemosensory region results in activation of a cluster of neurons within the ventrolateral preoptic area, which may promote sleep by inhibiting tuberomammillary nucleus, the source of the ascending histaminergic arousal system.

Microdialysis and EEG in rats reveal cortical PGE2 changes during sleep and wakefulness

Prostaglandin (PG) E2 production was assessed in freely moving rats using the technique of microdialysis in the prefrontal cortex associated with parallel cortical EEG recordings. PGE2 concentrations were 40% higher during wakefulness than during slow wave sleep. PGE2 values varied during wakefulness with a maximal increase in the middle of the stage and a drop towards lower values before the occurrence of slow wave sleep. These variations were similar to those observed previously in the rostromedial hypothalamus, where PGE2 concentration was 2.6 times lower than that in the cortex. These data document a positive correlation between cortical EEG activation and PGE2 levels. Taken together with pharmacological data on the awakening effect of centrally administered PGE2, these observations are in favor of an involvement of PGE2 in the generation of wakefulness.

Molecular mechanism of sleep regulation by prostaglandin D2

Recent biochemical, molecular biological, and pharmacological experiments revealed that prostaglandin D synthase as well as prostaglandin D2 circulated in the ventricular system, subarachnoidal space, and extracellular space in the brain. Prostaglandin D2 then interacts with chemosensors or receptors on the ventro-medial surface of the rostral basal forebrain to initiate the signal to promote sleep. Prostaglandin D2 is, therefore, not a typical neurotransmitter but rather a 'neurohormone' or an 'informational substance' that circulates through the cerebrospinal fluid and transmits certain chemical messages to promote sleep. The mode of communication through the cerebrospinal fluid in the ventricular system and the extracellular space has advantages for global regulation of the brain to induce sleep.

Astrocytes synthesize and secrete prostaglandin D synthetase in vitro

Prostaglandin D synthetase [PGD-S, prostaglandin-H2 D-isomerase, (5Z, 13E)-(15S)-9alpha, 11 alpha-epidioxy-15-hyrdroxyprosta-5,13-dienoate D-isomerase, EC 5,3,99,2], an enzyme that catalyzes the formation of prostaglandin D2, was originally isolated from homogenates of rat brain and spleen and is known to be a membrane-bound enzyme. Subsequent immunohistochemical studies have shown that PGD-S is associated with neurons in the brain of immature rats, whereas in adult rats it is associated with oligodendrocytes. Several recent studies have shown that the beta-trace protein isolated from human cerebrospinal fluid (CSF), the second most abundant protein in human CSF after albumin, is equivalent to PGD-S. In this paper, we report the preparation of a monospecific polyclonal antibody against purified PGD-S isolated from human CSF and the establishment of a specific radioimmunoassay for this protein. Using this radioimmunoassay in conjunction with immunoblot analysis, PGD-S was detected in various biological fluids including serum, aqueous humor, and rete testis fluid. In addition, an antibody prepared against human PGD-S partially cross-reacted with the PGD-S in the rat and ram. Using a monospecific polyclonal antibody prepared against purified rat PGD-S isolated from rat CSF in conjunction with [35S]methionine incorporation and immunoprecipitation techniques, it was shown for the first time that PGD-S is actively synthesized and secreted by astrocytes cultured in vitro, suggesting the astrocyte is the cellular origin of PGD-S in the CSF. The identification of the astrocyte as the cellular origin of this unique enzyme will allow the use of an in vitro system to study its regulation.

Decreased hypothalamic prostaglandin D2 and prostaglandin E2 contents during isoflurane anaesthesia in rats

This study was undertaken to evaluate the effect of isoflurane anaesthesia on the hypothalamic contents of both prostaglandin D2 and E2 which affect the sleep-wakefulness cycle. Sixty-three Wistar rats were divided into three equal groups, control, isoflurane and recovery groups. Twenty-one rats of the control did not receive isoflurane. In the other groups 21 rats received isoflurane 2% for 30 min and 21 received isoflurane 2% for 30 min and were allowed to recover their usual behaviours, including righting reflex, spontaneously. The hypothalamus was removed and the contents of PGD2 and PGE2 were measured by enzyme immunoassay. The PGD2 content in the hypothalamus was 397.9 +/- 226.0 pg.g-1 for the control group, 134.2 +/- 41.2 pg.g-1 for the isoflurane group and 269.1 +/- 124.6 pg.g-1 for the recovery group, respectively. The hypothalamic PGE2 contents were 381.4 +/- 139.0 pg.g-1 for the control group, 183.3 +/- 26.4 pg.g-1 for the isoflurane group and 312.2 +/- 96.0 pg.g-1 for the recovery group, respectively. The hypothalamic PGD2 and PGE2 contents in the isoflurane group were lower (P < 0.05) than those in the control and recovery groups, while both the PGD2 and PGE2 contents of the control and the recovery groups were similar. We conclude that decreased hypothalamic PGD2 and PGE2 contents may be related to some manifestations of general anaesthesia with isoflurane.

Changes in hypothalamic prostaglandin E2 may predict the occurrence of sleep or wakefulness as assessed by parallel EEG and microdialysis in the rat

Prostaglandin (PG) E2 is produced by mammalian hypothalamus and when administered exogenously prolongs wakefulness. In order to study the relation of endogenous hypothalamic PGE2 to sleep and wakefulness, we have used microdialysis in freely moving rats associated with EEG recording. Male Wistar rats were implanted with three cortical electrodes and with a guide cannula for microdialysis in the space between the paraventricular nucleus (PVN) and the ventromedial hypothalamus (VMH). PGE2 was measured by RIA in 3- or 6-min dialysates 15 days after surgery, when sleep patterns were normal again and PGE2 production stabilised. PGE2 levels were significantly higher during wakefulness (601 +/- 35 pg/ml, 5 experiments, 35 samples) than during slow-wave sleep (487 +/- 24 pg/ml, 5 experiments, 49 samples). Samples corresponding to paradoxical sleep showed a tendency towards higher PGE2 values compared to slow-wave sleep but lower compared to wakefulness. In epochs of wakefulness or sleep lasting at least 12 min, high PGE2 levels in the middle of wakefulness regularly dropped, thus announcing the occurrence of sleep. During sleep, PGE2 first went on dropping and then reincreased towards the values that characterize early periods of wakefulness. In its turn, this reincrease in PGE2 announced the end of sleep and the imminent occurrence of wakefulness. It is the first study to our knowledge showing that the evolvement in endogenous PG profile may predict the occurrence of sleep or wakefulness.

Prostaglandins E2 and D2 have little effect on rabbit sleep

Prostaglandins (PGs) are hypothesized to be involved in sleep regulation; PGE2 and PGD2 are major PGs in the hypothalamus of many species and are proposed to reciprocally promote wakefulness and sleep respectively. PGD2 and PGE2 are also major PGs in rabbit cerebrospinal fluid, yet their effects on rabbit sleep have not heretofore been systematically investigated. We report here that a bolus injection of PGE2 into a lateral cerebral ventricle induces dose-dependent fevers and transient sleep responses in rabbits. PGE2 induces a suppression of sleep of 24 min duration. In contrast, PGD2, across a wide range of doses (0.25-500 nmol) failed to alter sleep; however, at the highest dose it induced fever. We conclude that if PGs are involved in sleep regulation, a chronic stimulation of their production by other sleep factors is necessary.

Prostaglandin D2 inhibits pentylenetetrazole-induced convulsions in rats by a serotonin-mediated mechanism

Prostaglandins (PGs) of the E series are known to exert anticonvulsant action in experimental animals. Earlier studies from this laboratory have indicated that PGE1 inhibits pentylenetetrazole (PTZ)-induced convulsions in rats through a serotonin-mediated mechanism. PGD2, the major PG in the rodent brain, shares a number of central pharmacological actions of the PGEs, and like the latter it potentiates the anticonvulsant action of phenobarbitone and phenytoin in rats. The present study was undertaken to investigate the putative anticonvulsant action of PGD2 against PTZ-induced convulsions in rats and to evaluate the role of serotonin in the anticonvulsant action of PGD2. PGD2 (5, 10, and 20 micrograms, icv) produced a dose-related inhibition of PTZ-induced clonic convulsions in rats. The anticonvulsant action of PGD2 (20 micrograms, icv) was significantly attenuated following pretreatment of the rats with pharmacologic agents known to reduce central serotonergic activity, including 5,6-dihydroxytryptamine, a selective neurotoxin for serotonergic neurons, p-chlorophenylalanine, a specific inhibitor of serotonin biosynthesis, metergoline, a serotonin postsynaptic receptor antagonist, and quipazine, which is known to inhibit neuronal release of serotonin. These findings, in conjunction with an earlier study from this laboratory indicating that PGD2 augments rat brain serotonergic activity, suggest that the anticonvulsant activity of PGD2 against PTZ-induced convulsions in rats is mediated through a serotonergic mechanism.

Prostaglandin D2-induced catalepsy in rats: role of 5-hydroxytryptamine

Prostaglandin D2 (PGD2), the major PG in the rat brain, induced a dose-related catalepsy in rats on intracerebroventricular (i.c.v.) administration. This cataleptic response was significantly attenuated following the i.c.v. administration of pharmacological agents that decrease rat brain 5-hydroxytryptamine (5-HT) activity. PGE1 synergized but PGF2 alpha antagonized the catalepsy induced by PGD2. PGD2 and PGE1 have previously been shown to augment rat brain 5-HT activity, whereas PGF alpha inhibited it. It is therefore likely that the observed effects of these PGs on catalepsy involve a central 5-HT mechanism.

The effect of neurotransmitters on cataleptic behavior induced by PG D2 in rats

The effects of several neurotransmitters on prostaglandin (PG) D2-induced cataleptic behavior in rats were investigated by the high bar test. Intracerebroventricular administration of PG D2 elicited cataleptic behavior in a dose-dependent manner without producing a marked change in spontaneous motor activity. The incidences of cataleptic behavior were 20% and 100% at doses of 2 nmol and 50 nmol of PG D2, respectively. Intraperitoneal pretreatment with L-DOPA (100 mg/kg), apomorphine (1 mg/kg), amantadine (0.2 mg/kg), atropine (0.5 mg/kg) or p-chlorophenylalanine (300 mg/kg) significantly decreased the cataleptic behavior induced by 50 nmol of PG D2. Conversely, simultaneous treatment with 5-hydroxy-L-tryptophan (30 mg/kg), 5-methoxy-N,N-dimethyltryptamine (5 mg/kg), imipramine (20 mg/kg) or clomipramine (10 mg/kg) markedly increased the cataleptic behavior induced by 2 nmol of PG D2. Propranolol (10 mg/kg) and phenoxybenzamine (10 mg/kg) did not affect the induction of cataleptic behavior by either 2 nmol or 50 nmol of PG D2. These results suggest that PG D2 might be involved in inducing cataleptic behavior by modulating serotonergic, cholinergic and dopaminergic systems.

Protective effect of prostaglandins D2, E1 and I2 against cerebral hypoxia/anoxia in mice

The protective effect of prostaglandins (PGs) against cerebral hypoxia/anoxia was investigated with a variety of experimental models in relation to their CNS depressant effects in mice. Furthermore, the effect of PGs on the changes of cerebral energy metabolites and cyclic nucleotide was examined in hypoxic mice. Mice were given s.c. doses of PGs 30 min before tests. Among the PGs tested, treatment with PGD2, PGE1 and PGI2 Na showed a consistent and dose-dependent protection against cerebral anoxia induced by all models studied: histotoxic anoxia by KCN, hypobaric hypoxia, normobaric hypoxia and decapitation-induced gasping. However, PGA1, PGA2, PGB1, PGB2, PGE2, PGF1 alpha, PGF2 alpha and 6-keto-PGF1 alpha at a dose of 3 mg/kg were without effect against normobaric hypoxia and gasping duration. The three PGs, i.e. PGD2, PGE1 and PGI2 which showed anti-hypoxic effects decreased locomotor activity and potentiated hexobarbital-induced sleep. On the other hand, PGE2, PGA1, PGA2 and PGB2 also caused a decrease in locomotor activity. Similarly, PGE2 and PGA1 caused a potentiation of hexobarbital-induced sleep, but interestingly they did not cause clear-cut increase in cerebral resistance to hypoxia, in contrast with the former three PGs. Thus general depression of CNS function appears not to be responsible for the PGD2-, PGE1- and PGI2-induced increase in cerebral resistance to hypoxia. The levels of Cr-P and ATP were significantly reduced and those of ADP and AMP were markedly elevated in hypoxic brain, resulting in a decrease in a calculated energy charge potential. The lactate level and lactate/pyruvate ratio increased and the glucose level decreased markedly.(ABSTRACT TRUNCATED AT 250 WORDS)

Specificity of prostaglandin D2 binding to synaptic membrane fraction of rat brain

The structural requirement of the prostaglandin D2 molecule for binding to the synaptic membrane fraction of rat brain was extensively studied by using various prostaglandin D derivatives. Most strict specificity was found in the structures of the cyclo-pentane ring and the double bond in 13,14-position. The addition and deprivation of the double bond in alpha- and omega-chain, except on 13,14-position, moderately affected the binding. The modification in the carboxyl terminus and omega-chain terminus did not seriously influence the binding. BW 245C and 9-beta-prostaglandin D2, potent agonists for the prostaglandin D2 receptor in the platelet membrane, were almost ineffective. [3H]prostaglandin D2 binding was not affected by the addition of various neuroactive substances to the binding assay mixture. Further, prostaglandin D2 did not affect the known neurotransmitter receptor bindings in the rat brain.

Prostaglandin D2-induced potentiation of hexobarbitone hypnosis in rats: role of 5-hydroxytryptamine

Prostaglandin D2 (PGD2) produced a dose-related increase in the duration and incidence of induction of sleep induced by hexobarbitone, in rats. Pretreatment with pharmacological agents known to reduce selectively brain 5-hydroxytryptaminergic activity, significantly inhibited PGD2-induced potentiation of hexobarbitone, indicating that this potentiation is mediated by 5-hydroxytryptamine.

Involvement of the serotonergic system in the prolongation of pentobarbital sleeping time produced by prostaglandin D2

In the present study, the depressant and sedative actions of prostaglandin D2 (PGD2) were investigated. Intravenous (IV) administration of PGD2 produced a significant decrease in the spontaneous locomotor activity of mice from 1 to 15 minutes following injection. Prostaglandin D2 was also able to potentiate pentobarbital sleeping time at doses of 0.4 and 4.0 mg/kg when administered intravenously. Distribution studies with 3H-PGD2 (6 microCi, 4 mg/kg) showed that only 0.04% of the tritium administered could be found in brain at 5 min after the injection, and that only 50% of this was parent 3H-PGD2. The role of the serotonergic neurotransmitter system in the depressant action of PGD2 was investigated with drugs which modulate this system. The ability of PGD2 to potentiate pentobarbital sleeping time was diminished by pretreatment with agents that reduce brain level or synthesis rate of serotonin. Such agents include para-chlorophenylalanine (PCPA), a tryptophan hydroxylase inhibitor, 5,7-dihydroxytryptamine (5,7-DHT), a neurotoxin with selectivity for serotonergic neurons, and quipazine, a serotonergic autoreceptor stimulant. On the other hand, pretreatment with 5-hydroxytryptophan (5-HTP), the precursor of serotonin, further enhanced the potentiation of pentobarbital sleeping time by PGD2. These data suggest that the depressant actions of PGD2 are linked to the serotonergic neurotransmitter system.

Sedation produced by prostaglandins is not a nonspecific fatty acid effect

The fatty acid specificity of the depressant actions associated with prostaglandin (PG) administration was studied in mice. Administration of PG-E2 (0.4 and 1.0 mg/kg) or PG-D2 (0.4 and 4 mg/kg) significantly potentiated pentobarbital sleeping time. Arachidonic acid (3.3 mg/kg) administration also significantly potentiated pentobarbital sleeping time. Pretreatment with indomethacin (3 mg/kg) or ibuprofen (10 mg/kg) inhibited the potentiation of pentobarbital sleeping time produced by arachidonic acid. A nonspecific fatty acid (11, 14, 17-eicosatrienoic acid), which cannot be incorporated into the PG synthetic scheme, did not potentiate pentobarbital sleeping time. These results imply that the depressant activity associated with PG administration is a specific PG-induced action rather than a general effect of long-chain unsaturated fatty acids.

Autoradiographic localization of a binding protein(s) specific for prostaglandin D2 in rat brain

The specific [3H]prostaglandin (PG) D2 binding was detected by using the slide-mounted sections of rat brain fixed by perfusion with 2% paraformaldehyde. The binding was reversible, saturable, high affinity, Na+ dependent, and highly specific for PGD2. These binding characteristics are essentially similar to those observed with the synaptic membrane of rat brain as previously reported. Using autoradiographic image analyses by computerized densitometry and color coding, we visualized the localization of [3H]PGD2 binding in rat brain. A high density of the binding sites was observed in the cerebral cortex, preoptic area, amygdala, hypothalamic nuclei (arcuate nucleus, ventromedial nucleus, and posterior hypothalamic nucleus), thalamic nuclei (reuniens nucleus and rhomboid nucleus), hippocampus, pineal body, and cerebellar cortex. The binding was not significantly observed in the striatum and also was negative in the white matter, arachnoid membranes, and vasculatures.

Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha

The present work examined some central nervous actions of prostaglandin D2 (PGD2), which is the most prevalent prostaglandin in rodent brain. The effects of PGD2 were compared with those of PGE2 and PGF2 alpha. The prostaglandins were administered intracerebroventricularly (ICV) to conscious rats using the method of Herman (1970). All three prostaglandins studied produced depressive behavioral effects, causing obvious sedation at doses of 2.0 micrograms and 20.0 micrograms ICV. PGD2 and PGE2 significantly reduced spontaneous motor activity at doses of 2.0 micrograms and 20.0 micrograms ICV. PGF2 alpha was less effective; only 20.0 micrograms significantly inhibited motor activity. At a dose of 20.0 micrograms ICV all three compounds were shown to block convulsions induced by pentylenetetrazol. PGD2, the most effective prostaglandin in this respect, was still slightly anticonvulsive at a dose of 2.0 micrograms ICV. PGF2 alpha hat the weakest anticonvulsive potency. PGE2 and PGF2 alpha (2.0 micrograms and 20.0 micrograms ICV) caused a marked hypertensive effect, whereas PGD2 at the same dose levels only produced a small increase in blood pressure. PGE2 and PGF2 alpha (2.0 micrograms and 20.0 micrograms) also exerted marked pyrogenic actions. The effects of PGD2 on body temperature were variable. When given at a dose of 20.0 micrograms ICV, it caused slight hyperthermia whereas a lower dose (2.0 micrograms ICV) induced a moderate fall in body temperature. These findings suggest a relationship between the actions of the different prostaglandins on blood pressure and body temperature.